Johnson & Johnson (JNJ) Revenue (2008 - 2026)
Johnson & Johnson (JNJ) revenue from Jun 29, 2008 to Mar 29, 2026. The TTM Johnson & Johnson (JNJ) revenue is $96B. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual Revenue
Quarterly Revenue
Johnson & Johnson (JNJ) Revenue CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | +33.14% |
| 3 Years TTM | +13.92% |
| 5 Years TTM | +13.82% |
Annual Revenue change of Johnson & Johnson (JNJ)
| Year | Revenue | Change |
|---|---|---|
| 2026 | $24B | -74.45% |
| 2025 | $94B | +6.05% |
| 2024 | $89B | +4.30% |
| 2023 | $85B | +325.88% |
| 2022 | $20B | -75.79% |
| 2021 | $83B | +37.39% |
| 2020 | $60B | -26.75% |
| 2019 | $82B | +0.59% |
| 2018 | $82B | +6.71% |
| 2017 | $76B | N/A |
| 2016 | $0 | N/A |
| 2015 | $0 | N/A |
| 2014 | $0 | N/A |
| 2013 | $0 | N/A |
| 2012 | $0 | N/A |
| 2011 | $0 | N/A |
| 2010 | $0 | N/A |
| 2009 | $0 | N/A |
| 2008 | $0 | N/A |
| 2007 | $0 | N/A |
Comparison Johnson & Johnson (JNJ) five years revenue CAGR with competitors
Johnson & Johnson (JNJ) five years revenue CAGR is 2.73%.
| Ticker | Name | five years Revenue CAGR | Upside |
|---|---|---|---|
| LLY | Lilly(Eli) & Company | 23.17% | +748.23% |
| NVO | Novo Nordisk | 20.75% | +659.53% |
| AZN | Astrazeneca plc | 16.99% | +521.83% |
| MRK | Merck & Co Inc | 10.41% | +281.01% |
| AMGN | AMGEN Inc | 8.14% | +198.11% |
| PFE | Pfizer Inc | 6.56% | +140.12% |
| GRFS | Grifols SA | 5.39% | +97.47% |
| SNY | Sanofi | 5.03% | +84.06% |
| ABBV | Abbvie Inc | 4.59% | +67.99% |
| GILD | Gilead Sciences Inc | 3.07% | +12.37% |
| BMY | Bristol-Myers Squibb Company | 2.52% | -7.76% |
| NVS | Novartis AG | 2.36% | -13.63% |
| GSK | GSK Plc | 0.63% | -76.85% |